The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.
about
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease.Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN.Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).Emerging biologics in inflammatory bowel disease.Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know.Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.Bringing the Mucosa to Heal With Vedolizumab in Patients With Inflammatory Bowel Disease.Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.Precision Medicine in Inflammatory Bowel Diseases.Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.Anti-integrin therapy for inflammatory bowel disease.Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series
P2860
Q30234628-DF4A99DB-2F28-489E-A4B2-7422A3C911BEQ38643163-2B68C990-FABB-4486-9D59-AF467A70B4B4Q38671272-8C3E4C47-962A-49A0-8FCE-D5C27FF7DFFEQ38729864-4B950845-06A8-4392-BBC0-7CE345905DBAQ38865053-F9E125ED-0B0F-48F8-993C-4FEFA2A41E33Q39004625-83DAADC7-3098-454E-896E-BB66642505B0Q39140194-E7F90BD5-EFB7-4460-BCD7-93D5E0BF9C58Q41990775-6AA99B54-9F02-4C29-AA9F-CFBE7CECB413Q42065121-E524298D-F8ED-4A81-97E0-E718C71B99A5Q42695266-24A81456-4C96-4760-9DE4-679B6237EB05Q47282148-CEAB32B7-9735-4AD4-8C56-FD15FA698637Q47557672-769BDEBC-C1A8-4796-A4BA-E45EDEA7E009Q47703013-2CA80EAB-8FCC-46E1-B778-BCF186BA1238Q48102896-5E3EAB97-8E0D-4B2B-8FEC-D3E335177071Q48151874-9F615505-95CE-4A9E-9148-7D2E75E9F1F6Q48316242-F611A525-5C6D-4FBE-8135-F0E0BAF45235Q50012048-13067A73-778B-4080-BD99-1568A49BE071Q50205833-00A3739B-028D-410F-9DD2-6F24D35B779AQ50764332-348EA781-DA94-48CD-8A8C-AC97D5EAD61FQ51828636-E323BD5E-03A0-439B-AA4F-83516BDAFF6AQ52884617-3BF4A351-2995-4CE4-BE58-6F8F0645765EQ54530445-00F96C63-7D56-4E85-92C8-0E8D2CA2405FQ54976934-C7FAE25C-3F3D-410F-8988-9E7A932CC4E4Q55261138-08585493-8D7A-4B48-97F8-669514E57F5BQ55316690-B444053F-FF99-43C7-93C1-7766C61D42B8Q56968600-C893594D-787A-47D5-83E2-FAC3D545466B
P2860
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Real-World Effectiveness a ...... rom the US VICTORY Consortium.
@en
type
label
The Real-World Effectiveness a ...... rom the US VICTORY Consortium.
@en
prefLabel
The Real-World Effectiveness a ...... rom the US VICTORY Consortium.
@en
P2093
P2860
P50
P356
P1476
The Real-World Effectiveness a ...... From the US VICTORY Consortium
@en
P2093
Brigid S Boland
Bruce E Sands
Corey A Siegel
Dana Lukin
Diana Whitehead
Eugenia Shmidt
Farhad Peerani
Jean-Frederic Colombel
Khadija Chaudrey
Neeraj Narula
P2860
P304
P356
10.1038/AJG.2016.236
P407
P577
2016-06-14T00:00:00Z